Exalenz Bioscience To Begin Liver Disease Diagnostics Trial

October 23, 2014 | The Israeli biomedical company Exalenz Bioscience announced that their noninvasive diagnostics will now begin clinical trials for diagnosing diseases in the liver. Exalenz developed a system for diagnosing diseases in the digestive tract by testing the composition of the air in the patient’s mouth. Now the company will begin clinical trials to identify disease in the liver using the same method, but a different biological indicator. As a result, Exalenz’s share price rose 2 percent on the Tel Aviv Stock Exchange, giving the company a market cap of NIS 83.5 million.